Biogen Inc. Files Definitive Proxy Statement (DEF 14A)

Ticker: BIIB · Form: DEF 14A · Filed: 2024-04-26T00:00:00.000Z

Sentiment: neutral

Topics: Biogen, DEF 14A, Proxy Statement, Executive Compensation, Corporate Governance

TL;DR

<b>Biogen Inc. has filed its Definitive Proxy Statement (DEF 14A) for the period ending June 20, 2024.</b>

AI Summary

BIOGEN INC. (BIIB) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Biogen Inc. filed a Definitive Proxy Statement (DEF 14A) on April 26, 2024. The filing covers the period ending June 20, 2024. The company's principal executive offices are located at 225 Binney Street, Cambridge, MA 02142. Biogen Inc. was formerly known as Biogen Idec Inc. and Idec Pharmaceuticals Corp. The filing includes information related to executive compensation and equity awards for fiscal years 2020-2023.

Why It Matters

For investors and stakeholders tracking BIOGEN INC., this filing contains several important signals. This filing is crucial for shareholders to understand executive compensation structures and make informed voting decisions at the upcoming annual meeting. The detailed breakdown of equity awards and their year-over-year changes provides insight into management's incentives and the company's valuation of its talent.

Risk Assessment

Risk Level: low — BIOGEN INC. shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures on corporate governance and executive compensation without immediate financial or operational news.

Analyst Insight

Shareholders should review the executive compensation details and any proposed governance changes to inform their voting decisions.

Key Numbers

Key Players & Entities

FAQ

When did BIOGEN INC. file this DEF 14A?

BIOGEN INC. filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by BIOGEN INC. (BIIB).

Where can I read the original DEF 14A filing from BIOGEN INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by BIOGEN INC..

What are the key takeaways from BIOGEN INC.'s DEF 14A?

BIOGEN INC. filed this DEF 14A on April 26, 2024. Key takeaways: Biogen Inc. filed a Definitive Proxy Statement (DEF 14A) on April 26, 2024.. The filing covers the period ending June 20, 2024.. The company's principal executive offices are located at 225 Binney Street, Cambridge, MA 02142..

Is BIOGEN INC. a risky investment based on this filing?

Based on this DEF 14A, BIOGEN INC. presents a relatively low-risk profile. The filing is a routine DEF 14A, providing standard disclosures on corporate governance and executive compensation without immediate financial or operational news.

What should investors do after reading BIOGEN INC.'s DEF 14A?

Shareholders should review the executive compensation details and any proposed governance changes to inform their voting decisions. The overall sentiment from this filing is neutral.

How does BIOGEN INC. compare to its industry peers?

Biogen Inc. operates in the biotechnology sector, focusing on the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases.

Are there regulatory concerns for BIOGEN INC.?

As a publicly traded company, Biogen Inc. is subject to SEC regulations, including the requirement to file proxy statements (DEF 14A) for shareholder meetings.

Industry Context

Biogen Inc. operates in the biotechnology sector, focusing on the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases.

Regulatory Implications

As a publicly traded company, Biogen Inc. is subject to SEC regulations, including the requirement to file proxy statements (DEF 14A) for shareholder meetings.

What Investors Should Do

  1. Review the detailed executive compensation tables for fiscal years 2020-2023.
  2. Analyze any proposals related to corporate governance presented for shareholder vote.
  3. Note the company's historical name changes and incorporation details.

Key Dates

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard disclosure document for public companies regarding their annual shareholder meetings and executive compensation. No direct comparison to a prior filing's financial performance is available in this document type.

Filing Stats: 4,412 words · 18 min read · ~15 pages · Grade level 16.8 · Accepted 2024-04-26 17:01:24

Key Financial Figures

Filing Documents

Executive Compensation Philosophy

Executive Compensation Philosophy Our executive compensation philosophy is to reward executives for the creation of long-term stockholder value. We designed performance-based compensation that is competitive with our peer group to attract and retain extraordinary leaders who perform at high levels and succeed in a demanding business environment. Mission Focused and Business Driven Competitively Advantageous Performance Differentiated Ownership Aligned We emphasize the importance of achieving short-term goals while building and sustaining a foundation for long-term success in delivering meaningful and innovative therapies to patients We benchmark against companies we compete with for talent and our compensation is designed to recruit, retain and motivate our leadership team to achieve their best for the company and our stockholders We endeavor to align pay outcomes with company and individual performance and reward our best performers for exceeding expectations We provide equity to all of our employees to align their interest with our broader interest of creating long-term value for our stockholders How Our Pay Practices Align with Our Philosophy Practice Mission Focused / Business Driven Competitively Advantageous Performance Differentiated Ownership Aligned Over 85% of NEO (excluding the CEO) total direct compensation is tied to performance driven measurements Annual bonus and LTI plan are performance-based with payouts capped LTI awards are linked to performance, subject to multi-year vesting periods, and designed to reward long-term performance Competitive total pay opportunities relative to peer group and broader market in which we compete for talent Annual risk assessment to ensure our compensation programs do not encourage excessive risk taking Robust stock ownership, anti-hedging and pledging, and clawback policies Stockholder feedback is a key input to Board and CMDC discussions and informs actions taken 2024 Proxy

Executive Compensation Philosophy

Executive Compensation Philosophy 30 Compensation Elements 30 Compensation Mix 31 Our Named Executive Officers for 2023 31 2023 Base Salary 31 2023 Performance-Based Plans and Goal Setting 32 Performance Goals and Target Setting Process 32 Changes Implemented for 2024 STI Program 33 Changes Implemented for 2024 LTI Program 39 Roles and Responsibilities 43 External Market Competitiveness and Peer Group 44 Retirement Plans 45 Other Benefits 45 Post-Termination Compensation and Benefits 46 Stock Ownership Guidelines 46 Recoupment of Compensation 46 Insider Trading, Hedging and Pledging Policy Prohibitions 46 Tax-Deductibility of Compensation 47 Compensation Committee Report 47

Executive Compensation Tables

Executive Compensation Tables 48 Summary Compensation Table 48 2023 Grants of Plan-Based Awards 49 Outstanding Equity Awards at 2023 Fiscal Year-End 51 2023 Option Exercises and Stock Vested 52 2023 Non-Qualified Deferred Compensation 52 Potential Payments Upon Termination or Change in Control 53 CEO Pay Ratio 56 Pay for Performance 57 Proposal 4 – Amendment of the Amended and Restated Certificate of Incorporation, as amended, to add an Officer Exculpation Provision 60 Proposal 5 – Approval of Biogen Inc. 2024 Omnibus Plan 62 Proposal 6 – Approval of Biogen Inc. 2024 Employee Stock Purchase Plan 67 Stock Ownership 70 Information About the Meeting 72 Miscellaneous 79 Other Stockholder Communications 80 Incorporation by Reference 80 Copies of Annual Meeting Materials 81 Manner and Cost of Proxy Solicitation 81 Appendix A – GAAP to non-GAAP Reconciliation A-1 Appendix B – Certificate of Amendment of Amended and Restated Certificate of Incorporation, as amended B-1 Appendix C – Biogen Inc. 2024 Omnibus Plan C-1 Appendix D – Biogen Inc. 2024 Employee Stock Purchase Plan D-1 2024 Proxy Statement Table of Contents Proxy Statement Summary Proxy Statement Summary This summary highlights important information you will find in this Proxy Statement. As it is only a summary, please review the complete Proxy Statement before you vote. Annual Meeting Information DATE: Thursday, June 20, 2024 TIME: 9:00 a.m. Eastern Time LOCATION: Online only at www.virtualshareholdermeeting.com/BIIB2024 You will not be able to attend the annual meeting in person. RECORD DATE: April 25, 2024 Voting Matters and Vote Recommendation Matter Management Proposals: Our Board Recommendation Page Number for more detail Proposal 1—Election of Directors FOR each nominee 2 Proposal2—Ratificationof the Selection of PwC as our Independent Registered Public Accounting Firm FOR 22 P

View on Read The Filing